Hylife Biotech stands at the helm of a consortium comprising seven partners, spearheading the Australian regenerative medicine (RM) industry's journey towards prosperity and fostering significant contributions to both the Australian economy and the well-being of its citizens.

Over the course of 12 months, this project aims to pinpoint and establish a national collaboration body serving as a 'catalyst' for the RM sector, addressing critical action areas such as enhancing workforce capabilities, fostering collaboration, securing funding, shaping regulatory and policy frameworks, and bolstering Australian manufacturing prowess.